Clinical Trial

Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 20, 2024 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
To investigate the predictive value of stathmin expression as a predictive biomarker in OSCC patients, who treated with TPF (docetaxel, cisplatin and 5-fluorouracil ) induction chemotherapy followed by radical surgery and radiotherapy/chemoradiotherapy.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2017-10-26; most recent amendment 2024-02-17.
Status change: Not Yet Recruiting → Recruiting 2020-01-09
Trial Details
NCT Number NCT03326947
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Conditions Neoplasm Neck
Enrollment 60 participants
Start Date 2018-01-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2024-02-20